Fall 2026
Software Engineer Intern
Washu IT
Posted on 7/4/2026
Wash U
Academic research and entrepreneurial institution
No salary listed
St. Louis, MO, USA
In Person
On-site internship at Washington University Medical Campus in St. Louis, MO.
 Software Engineering (1) |
|---|
- No specific education is required for this position.
- No specific certification/professional license is required for this position.
- No specific work experience is required for this position.
- A driver's license is not required for this position.
- Skills: Not Applicable
- Develop, test, and maintain tools, scripts, and services that support research workflows on the HPC cluster (e.g., job submission helpers, workflow automation, monitoring tools).
- Contribute to internal web applications, command-line tools, or APIs that simplify HPC usage for researchers.
- Assist with integrating new research applications and libraries into the cluster environment.
- Follow software engineering best practices including version control, code reviews, issue tracking, and testing.
- Write clean, maintainable, and well-documented code.
- Help identify and implement improvements to development processes and tooling.
- Configure, build, and test scientific software, libraries, and containerized applications (e.g., Singularity/Apptainer, Docker) for use on the cluster.
- Contribute to performance testing and benchmarking of applications, analyzing results and suggesting improvements.
- Support efforts to improve usability, reliability, and automation within the HPC software stack.
- Education: No additional education unless stated elsewhere in the job posting.
- Certifications/Professional Licenses: No additional certification/professional licenses unless stated elsewhere in the job posting.
- Work Experience: No additional work experience unless stated elsewhere in the job posting.
- Skills: Analytical Thinking, Artificial Intelligence Algorithms, C++ Programming Language, Communication, Data Analysis, Feature Engineering, Git, Independent Problem Solving, JavaScript, Linux Environments, Machine Learning (ML), Python (Programming Language), PyTorch, scikit-learn, Tensorflow, Web Application Frameworks, Work Collaboratively
Wash U translates academic research into practical technologies and programs that address global challenges. The institution supports scholars through grants and partnerships to move discoveries from the lab into the public sector via entrepreneurship and technology transfer. Unlike many traditional research institutions, Wash U emphasizes a high level of financial transparency and leverages a historical connection to Nobel Laureates to foster a collaborative environment. Its goal is to use these shared visions and research initiatives to create a more equitable future and provide tangible benefits to society.
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
N/A
Founded
1853
Simplify's Take
What believers are saying
- July 2026 Wentzville pediatric center expands WashU-BJC patient volume and referral gravity.
- June 2026 NIH awarded $3.5 million to WashU's prenatal opioid neurodevelopment program.
- April 2026 Bristol Myers Squibb collaboration funds translational neuroscience training and research pipelines.
What critics are saying
- October 2025 layoffs cut 316 jobs and 198 vacancies, signaling continuing budget pressure.
- January 2026 AFL complaint targets WashU DEI programs, risking DOJ scrutiny and grant disruptions.
- Federal funding dependence and a $37 million endowment tax amplify existential margin pressure.
What makes Wash U unique
- WashU Medicine holds the second-largest NIH portfolio and spent over $1.6 billion annually.
- The BJC joint Center for Health AI gives WashU a system-level clinical AI sandbox.
- WashU monetizes research quickly, like Neuraptive's July 2026 licensed bioresorbable nerve stimulator.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
401(k) Company Match
Wellness Program
Mental Health Support
Parental Leave
Family Planning Benefits
Company News
Lee and Lee honored with prestigious Cogan Award. August 7, 2026 Aaron Y. Lee, MD, the Arthur W. Stickle Distinguished Professor of Ophthalmology and Visual Sciences and head of the John F. Hardesty, MD Department of Ophthalmology & Visual Sciences at WashU Medicine, and Cecilia Lee, MD, the Jane Hardesty Poole Distinguished Professor, have been honored with the Cogan Award in recognition of their impactful contributions to vision science and ophthalmic research. This prestigious award, presented by the Association for Research in Vision and Ophthalmology (ARVO), highlights exceptional work that propels the field forward through innovative methods and collaborative leadership. Their recognition underscores WashU Medicine's leadership in combining clinical excellence, innovative research and collaborative science to address some of the most challenging questions in vision care. Lee and Lee harness large-scale data, machine learning and advanced analytics to elucidate complex patterns in eye disease and vision loss, while also leveraging the eye as a non-invasive window into systemic health - a field known as oculomics. Their research emphasizes equitable access to data and analytic tools, ensuring that discoveries benefit diverse populations and accelerate real-world translational impact.
Which health systems have chief AI officers. Table of contents. As hospitals and health systems further embed AI into healthcare delivery, they are increasingly appointing chief AI officers or equivalent senior executives with dedicated responsibility for AI governance, implementation and oversight, reflecting a broader trend of health systems chief AI officers taking on formalized C-suite roles. Why health systems chief AI officers roles are growing. The growing presence of these roles reflects the industry's recognition that AI may pose risks to patient safety, professional liability and regulatory compliance, and thus warrants cross-functional leadership at the highest levels. Below is a look at healthcare organizations with dedicated AI leadership. Academic medical centers leading with health systems chief AI officers. Ann & Robert H. Lurie Children's Hospital of Chicago named Rajiv Kolagani as its chief data and AI officer. BJC Health System and WashU Medicine in St. Louis appointed two leaders: Philip R.O. Payne, PhD, as the inaugural chief health AI officer of WashU Medicine and BJC, and Deborah O'Dell as chief data & analytics officer at BJC. Major health systems with chief AI officers on the west coast. Cedars-Sinai in Los Angeles appointed Mouneer Odeh as its inaugural chief artificial intelligence officer at the end of 2024. City of Hope in Duarte, Calif., named Nasim Eftekhari system vice president and chief AI and analytics officer. UCLA Health named Paul J. Lukac, MD, as its chief AI officer, while UCSF Health named Sara Murray, MD, as chief health AI officer. UC San Diego Health named Karandeep Singh, MD, as its inaugural chief health artificial intelligence officer, and UCI Health in Orange, Calif., named Deepti Pandita, MD, as its chief medical informatics and AI officer. Kaiser Permanente's approach to AI leadership. Kaiser Permanente in Oakland, Calif., has Daniel Yang, MD, serving as vice president of artificial intelligence and emerging technologies, a title distinct from the "chief AI officer" designation used at many peer organizations. Midwest and southern health systems chief AI officers. Cleveland Clinic appointed Ben Shahshahani, PhD, as its first vice president and chief artificial intelligence officer in August 2024. Mayo Clinic in Rochester, Minn., appointed Micky Tripathi, PhD, as its chief AI implementation officer, while Mayo Clinic Arizona in Phoenix separately named Bhavik Patel, MD, as chief AI officer. Mercy in St. Louis named Byron Yount, PhD, as chief data and artificial intelligence officer and vice president of transformation operations. Additional regional health systems naming AI chiefs. Baptist Health System in Louisville, Ky., named Brett Oliver, MD, as its chief medical information and AI officer. Bon Secours Mercy Health in Cincinnati named Dylan Clark as its chief analytics and artificial intelligence officer. University of Utah Health in Salt Lake City appointed Kensaku Kawamoto, MD, PhD, as its first chief health AI transformation officer. UT Southwestern Medical Center in Dallas named Warren D'Souza, PhD, as its inaugural chief artificial intelligence officer, and VCU Health in Richmond, Va., named Alok Chaudhary as vice president and chief data and artificial intelligence officer. Children's Hospitals and Denver Health's AI Leadership. Children's National Hospital in Washington, D.C., named Alda Mizaku as vice president and chief data and AI officer. Denver Health named Daniel Kortsch, MD, as its associate chief of AI and digital health. Hackensack Meridian Health in Edison, N.J., named David Arnold as its senior vice president and chief AI and data officer. Variation in title and scope across these health systems chief AI officers. Across this list, titles vary meaningfully, from "chief AI officer" to "chief health AI officer" to "vice president of artificial intelligence and emerging technologies," reflecting differing organizational structures and how each health system chooses to position AI leadership relative to existing informatics, data, and analytics functions. What this wave of health systems chief AI officers means going forward. With more than 20 major health systems now represented on this list, spanning academic medical centers, children's hospitals, and regional systems across the country, the appointment of dedicated AI leadership appears to have become a standard organizational response to AI's growing role in clinical and administrative operations. Given the cross-functional nature of these roles, spanning patient safety, professional liability, and regulatory compliance, other health systems without a formally designated AI chief may increasingly feel competitive pressure to establish similar positions. What to watch going forward. As this list continues to grow, with Becker's actively soliciting additional health systems for inclusion, industry observers will likely watch which organizational models, dedicated chief AI officer roles versus AI responsibilities folded into existing chief medical information officer or chief data officer positions, prove most effective at balancing innovation with the governance and compliance demands these executives are tasked with managing. Given how recently many of these appointments occurred, with several dating to only the past one to two years, this health systems chief AI officers trend appears to still be in its early, rapidly evolving phase across the healthcare industry.
WashU announces new academic-industry collaboration with Bristol Myers Squibb. Multiyear program will provide hands-on training at the pharmaceutical company, fund translational neuroscience research at WashU Washington University in St. Louis and Bristol Myers Squibb have formed a multiyear collaboration to foster scientific exchange between academia and industry in the field of neuroscience. Through this agreement, WashU medical and research trainees will have opportunities to work alongside Bristol Myers Squibb teams on select drug development projects. The collaboration builds on a long-standing research relationship aimed at combining WashU's expertise in fundamental and clinical research in neurodegenerative diseases with Bristol Myers Squibb's extensive experience in drug discovery and development. It also will provide unique opportunities for WashU Medicine trainees to gain embedded industry experience. "This partnership represents a powerful model for how academia and industry can work together to advance neuroscience," said Doug E. Frantz, WashU's vice chancellor for innovation and commercialization. "By pairing our strengths in fundamental and clinical neuroscience with Bristol Myers Squibb's deep expertise in drug development, we have an opportunity to accelerate breakthrough discoveries toward meaningful therapies for patients. At the same time, integrating our residents and fellows within Bristol Myers Squibb ensures we are training the next generation of physician-scientists in the full continuum of translational science." Each year, the program will provide funding to support up to three visiting fellows at Bristol Myers Squibb and three translational research programs at WashU in the neurosciences, with the goal of developing potential new therapeutics for neurological, neuromuscular, neuroinflammatory and psychiatric conditions. "This collaboration reinforces our commitment to working together with the goal to advance innovation that can help address significant unmet needs in neurodegenerative and neuropsychiatric diseases," said Peter Paine, head of strategic partnerships for Bristol Myers Squibb. "These conditions represent some of the greatest health challenges of our time, and we look forward to working with WashU to pursue transformational treatments for patients." WashU faculty have long collaborated with Bristol Myers Squibb on specific studies or within larger academia-industry initiatives such as the Neurofilament Light Consortium, a collaboration among WashU Medicine, University College London and several pharmaceutical companies, including Bristol Myers Squibb, to investigate neurodegenerative diseases. The new collaboration creates a formal structure to form and fund research projects in priority areas for both WashU and Bristol Myers Squibb. The goal of the agreement is ultimately to advance the field of neuroscience in ways that lead to improved treatments and patient outcomes. Private-sector partnerships with universities are usually narrow in scope, funding a pre-defined set of projects. In contrast, the high-level joint commitment of this new collaboration focuses on training the next generation of leaders in neuroscience to be proficient in both academic and industry settings. Melanie Roewe, associate vice chancellor of research administration at WashU, said that the mutual enthusiasm was reflected in the speed and ease with which the agreement came together. "This is an elevated relationship, different from most collaborations," said Roewe. "Both sides are invested in finding new and productive ways to work together and continually furthering what this collaboration can achieve." Program participation. Individuals interested in participating in the visiting fellows program or the translational neuroscience research program are encouraged to submit an expression of interest by Sept. 1. For additional information regarding eligibility, participation and the expression-of-interest process, reach out to Mark Van Horn, senior director of business development, Strategic External Projects and Outreach, at [email protected]. About WashU Medicine WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with more than 3,000 faculty. Its National Institutes of Health (NIH) research funding portfolio is the second largest among U.S. medical schools and has grown 83% since 2016. Together with institutional investment, WashU Medicine commits well over $1 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently among the top five in the country, with more than 2,000 faculty physicians practicing at 130 locations. WashU Medicine physicians exclusively staff Barnes-Jewish and St. Louis Children's hospitals - the academic hospitals of BJC HealthCare - and Siteman Cancer Center, a partnership between BJC HealthCare and WashU Medicine and the only National Cancer Institute-designated comprehensive cancer center in Missouri. WashU Medicine physicians also treat patients at BJC's community hospitals in its region. With a storied history in MD/PhD training, WashU Medicine recently dedicated $100 million to scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in every medical subspecialty as well as physical therapy, occupational therapy, and audiology and communications sciences.
Global AI movements & new biological pathways. Focus: Aligning Glassbury AI's engineering approach with the massive global computational shift and a newly discovered cellular death mechanism. 1. "The C-BRAIN consortium: what an 'AI biomedical research scientist' means for Glassbury's tech stack" * The Hook: On July 13, 2026, a global coalition of academic centers (led by WashU Medicine) and pharma giants launched C-BRAIN. Its mission? Building open-source AI tools to attack the notorious 99% failure rate of neurodegenerative clinical trials by synthesizing "dark" (unpublished) data and clinical literature. * The Angle: Write an insider piece on how Glassbury AI views this watershed moment. Explain that the era of isolated, proprietary "black box" medical AI is ending. Detail how Glassbury's own pipelines plan to leverage and interface with C-BRAIN's open-source frameworks, establishing Glassbury as an early adopter of standardized, collaborative medical AI. * Why It Matters Now: This is the biggest medical-AI news of the summer. Aligning Glassbury with a major global consortium shows that your team is at the absolute forefront of industry standards.
Neuraptive secures exclusive licence from Washington University for nerve device. The newly licensed device will be added to Neuraptive's portfolio, which includes NTX-001, currently in Phase III clinical evaluation. Neuraptive Therapeutics has secured an exclusive licence from Washington University in St Louis for a bioresorbable wireless electronic stimulation device designed for peripheral nerve repair. The technology, which was developed at Washington University School of Medicine (WashU Medicine) in collaboration with Northwestern University, delivers targeted electrical pulses to damaged nerves to support regeneration. The device is said to be fully bioresorbable and does not require a second procedure for removal, as it naturally breaks down in the body over time. The newly licensed device will be added to Neuraptive Therapeutics' existing portfolio, which includes NTX-001, a nerve fusion system currently being studied in a Phase III trial for surgical repair of transected peripheral nerves. Washington University in St Louis office technology management assistant vice chancellor and managing director Nichole Mercier said: "WashU is excited to partner with an emerging company like Neuraptive to support the development of the bioresorbable platform originating from its research labs. "This agreement enables the platform to be further developed to advance peripheral nerve repair and have patient impact." Neuraptive Therapeutics chairman and CEO Bob Radie said: "This deal is a meaningful step in strengthening its portfolio and offering more options for patients facing nerve injuries. "The bioresorbable stimulator has real potential either on its own for repairing severed nerves or as a synergistic complement to its lead product candidate, NTX-001. "Medical Device Network also intend to build on promising early research into the device's ability to help speed recovery from crushed nerves. "Overall, this technology could add a broader set of tools for surgeons and patients, aiming for better functional recovery, fewer long-term issues, and improved quality of life after these challenging injuries." Earlier this year, Washington University School of Medicine (WashU Medicine) researchers developed an Alzheimer's blood test symptom prediction model that estimates when individuals may begin to show signs of the disease. Give your business an edge with its leading industry insights.